First Trust Nasdaq Pharmaceuticals ETF (FTXH)
Price:
29.27 USD
( - -0.06 USD)
Your position:
0 USD
ACTION PANEL
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
ProShares UltraShort Nasdaq Biotechnology
VALUE SCORE:
9
2nd position
Angel Oak Ultrashort Income ETF
VALUE SCORE:
12
The best
Invesco Variable Rate Investment Grade ETF
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.
NEWS
Trump announces 100% tariffs on pharmaceutical drugs, beginning October 1
fastcompany.com
2025-09-26 13:22:58President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks starting on Oct. 1.The posts on his social media site showed that Trump's devotion to tariffs did not end with the trade frameworks and import taxes that were launched in August, a reflection of the president's confidence that taxes will help to reduce the government's budget deficit while increasing domestic manufacturing.While Trump did not provide a legal justification for the tariffs, he appeared to stretch the bounds of his role as commander-in-chief by stating on Truth Social that the taxes on imported kitchen cabinets and sofas were needed “for National Security and other reasons.”Under the Trade Expansion Act of 1962, the administration launched a Section 232 investigation in April about the impacts on national security from pharmaceutical drug and truck imports.
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
zacks.com
2025-09-26 10:26:08Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
A Look at Pharma ETFs After Strong Q1 Earnings
zacks.com
2025-05-08 12:50:40Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
Pharma ETFs in Focus Post Solid Q2 Earnings
zacks.com
2024-08-14 12:51:07Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
A Look at Pharma ETFs Post Q1 Earnings
zacks.com
2024-05-07 12:31:03Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
zacks.com
2024-04-17 11:00:19Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
A Look at Pharma ETFs After Q4 Earnings
zacks.com
2024-02-12 14:01:05The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Pharma ETFs in Focus Post Q3 Earnings
zacks.com
2023-11-08 12:46:40Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Pharma ETFs in Focus Post Q2 Earnings
zacks.com
2023-08-11 13:47:31Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.
5 ETFs to Buy on JNJ's Q2 Earnings Strength
zacks.com
2023-07-21 11:27:16Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.
Biotech ETFs in Focus on Covid Vaccines' Fall Rollout
zacks.com
2023-06-22 15:37:10The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.
Pharma ETFs Gain Post Q1 Earnings
zacks.com
2023-05-09 13:01:28Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
Can Health Care Stocks Outperform Again In 2023?
seekingalpha.com
2023-01-11 18:09:00How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
5 Best Sector ETFs of 2022
zacks.com
2022-12-14 14:18:04Here are the top-performing sector ETFs of 2022. These include energy, healthcare, materials, utilities and consumer staples.
Amgen to Buy Horizon Therapeutics: ETFs to Bet On
zacks.com
2022-12-13 12:48:18Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.
2 Sector ETFs Hovering Around a 52-Week High
zacks.com
2022-12-06 14:18:05We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.
No data to display
Trump announces 100% tariffs on pharmaceutical drugs, beginning October 1
fastcompany.com
2025-09-26 13:22:58President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks starting on Oct. 1.The posts on his social media site showed that Trump's devotion to tariffs did not end with the trade frameworks and import taxes that were launched in August, a reflection of the president's confidence that taxes will help to reduce the government's budget deficit while increasing domestic manufacturing.While Trump did not provide a legal justification for the tariffs, he appeared to stretch the bounds of his role as commander-in-chief by stating on Truth Social that the taxes on imported kitchen cabinets and sofas were needed “for National Security and other reasons.”Under the Trade Expansion Act of 1962, the administration launched a Section 232 investigation in April about the impacts on national security from pharmaceutical drug and truck imports.
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
zacks.com
2025-09-26 10:26:08Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
A Look at Pharma ETFs After Strong Q1 Earnings
zacks.com
2025-05-08 12:50:40Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
Pharma ETFs in Focus Post Solid Q2 Earnings
zacks.com
2024-08-14 12:51:07Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
A Look at Pharma ETFs Post Q1 Earnings
zacks.com
2024-05-07 12:31:03Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
zacks.com
2024-04-17 11:00:19Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
A Look at Pharma ETFs After Q4 Earnings
zacks.com
2024-02-12 14:01:05The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Pharma ETFs in Focus Post Q3 Earnings
zacks.com
2023-11-08 12:46:40Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Pharma ETFs in Focus Post Q2 Earnings
zacks.com
2023-08-11 13:47:31Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.
5 ETFs to Buy on JNJ's Q2 Earnings Strength
zacks.com
2023-07-21 11:27:16Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.
Biotech ETFs in Focus on Covid Vaccines' Fall Rollout
zacks.com
2023-06-22 15:37:10The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.
Pharma ETFs Gain Post Q1 Earnings
zacks.com
2023-05-09 13:01:28Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
Can Health Care Stocks Outperform Again In 2023?
seekingalpha.com
2023-01-11 18:09:00How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
5 Best Sector ETFs of 2022
zacks.com
2022-12-14 14:18:04Here are the top-performing sector ETFs of 2022. These include energy, healthcare, materials, utilities and consumer staples.
Amgen to Buy Horizon Therapeutics: ETFs to Bet On
zacks.com
2022-12-13 12:48:18Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.
2 Sector ETFs Hovering Around a 52-Week High
zacks.com
2022-12-06 14:18:05We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.